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Abstract
 
In a transgenic model of multi-stage squamous carcinogenesis induced by human papillomavi-
rus (HPV) oncogenes, infiltrating CD4
 

 
 T cells can be detected in both premalignant and ma-
lignant lesions. The lymph nodes that drain sites of epidermal neoplasia contain activated
CD4
 

 
 T cells predominantly reactive toward Staphylococcal bacterial antigens. HPV16 mice
deficient in CD4
 

 
 T cells were found to have delayed neoplastic progression and a lower inci-
dence of tumors. This delay in carcinogenesis is marked by decreased infiltration of neutrophils,
 
and reduced activity of matrix metalloproteinase-9, an important cofactor for tumor progression
in this model. The data reveal an unexpected capability of CD4 T cells, whereby, proinflamma-
tory CD4
 

 
 T cells, apparently responding to bacterial infection of dysplastic skin lesions, can
inadvertently enhance neoplastic progression to invasive cancer.
Key words: mice • transgenic • cancer • inflammation • lymphocyte
 
Introduction
 
All tumors of epithelial origin are composed of multiple
cell types that include both transformed genetically altered
cells and several nontransformed cell types, including fibro-
blasts, endothelial cells, macrophages, neutrophils, mast
cells, and lymphocytes. We have studied a transgenic
mouse model of epithelial carcinogenesis wherein the hu-
 
man papillomavirus type 16 (HPV16)
 
*
 
 early region genes
are expressed in the basal keratinocytes under the control of
the human keratin 14 promoter (1). The K14-HPV16
mice show multistage development of invasive squamous
cell carcinoma (SCC) of the epidermis (2). The pathway is
characterized by a phenotypically normal epidermis at
birth, followed by the development of epidermal hyperpla-
sia beginning at one month of age, and subsequent focal
progression to highly angiogenic dysplasias between 3 and
6 mo of age (3, 4). The dysplasias are characterized by mast
cell and neutrophil infiltration of the reactive stroma, and
by increased density and altered architecture of the vascula-
ture. By 1 yr of age, 
 

 
50% of transgenic mice develop in-
vasive carcinomas, of which 
 

 
30% metastasize to regional
lymph nodes.
A protease, matrix metalloproteinase-9 (MMP-9), has
been revealed as a functional contributor to squamous epi-
thelial carcinogenesis in K14-HPV16 mice; and remark-
ably, bone marrow-derived inflammatory cells are a suf-
ficient source of the MMP-9 for its demonstrable
contributions to malignant progression (5). The realization
that a protease supplied by infiltrating immune cells is fuel-
ing neoplastic progression in mouse models of skin and
pancreatic islet cancer (5, 6) comes amidst increasing exper-
imental evidence linking inflammation and cancer (7). In-
flammation has been predominantly viewed as beneficial to
the host and deleterious to tumors (8), although a variety of
circumstantial evidence has long suggested the possibility
that inflammatory responses can enhance carcinogenesis
(9). Recent studies using gene knockout mice and other
tools to probe functional roles have substantiated the capa-
bility of immune cells to enhance cancer phenotypes, in tu-
mor models involving orthotopically transplanted neoplas-
tic cells, chemically induced cancers, as well as in transgenic
mouse models (10–13).
In this report, we investigated the abundance and possi-
ble roles of CD4
 

 
 and CD8
 

 
 T lymphocytes during epi-
thelial carcinogenesis in K14-HPV16 mice. CD4
 

 
 T cells
were found to be infiltrating both premalignant skin lesions
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*
 
Abbreviations used in this paper:
 
 HPV16, human papillomavirus type 16;
MMP-9, matrix metalloproteinase-9;
 
 
 
SCC, squamous cell carcinoma.
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and SCCs. We initially hypothesized that the T cell infil-
tration was intended to antagonize malignant progression
by an immune surveillance mechanism. To test this hy-
pothesis, we crossed the K14-HPV16 mice to mice with
homozygous deletions of the genes encoding the CD4 or
CD8 coreceptors. Unexpectedly, the data revealed that in-
filtrating CD4
 

 
 T cells were functionally promoting epi-
thelial carcinogenesis and that their predominant reactivity
was toward Staphylococcal antigens, not the HPV16 onco-
genes, likely in response to extensive 
 
Staphylococcus
 
 coloni-
zation of the neoplastic epidermis.
 
Materials and Methods
 
K14-HPV16 Transgenic, CD4 Null, and CD8 Null Mice.
 
The
K14-HPV16 transgenic mice (1) and the characterization of neo-
plastic stages based on hematoxylin and eosin staining and keratin
intermediate filament expression for histologic examination have
been reported previously (2). Histologic grading criteria of low
versus high grade hyperplastic lesions consisted of examination of
epidermal thickness, presence of hyperchromatic nuclei in supra-
basal epidermis, and presence of an intact granular cell layer con-
taining prominent keratohyalin granules and flattened cellular
morphology. Histologic grading criteria for low grade dysplastic
lesions consisted of greater than twofold increase in the thickness
of the epidermis with basal and spinous keratinocytes present
throughout the epidermis, focal loss of keratohyalin granules, and
appearance of keratinocytes with rounded morphology through-
out entire suprabasal compartment. High grade dysplastic lesions
were positively scored based on presence of an epidermis exclu-
sively containing basal and spinous keratinocytes with hyperchro-
matic nuclei, complete loss of keratohyalin granule containing
cells, and extensive rete ridging of the basement membrane. The
K14-HPV16 mice were maintained in the FVB/n background
(FVB/n; The Jackson Laboratory). The generation of CD4 ho-
mozygous null animals (14) and CD8
 

 
 homozygous null animals
(15) has been reported. CD4
 

 
/
 

 
 mice were bred 14 generations
into FVB/n (FVB/n; The Jackson Laboratory) before intercross-
ing with HPV16 transgenic mice (N21 FVB/n), in turn produc-
ing CD4-deficient HPV16 mice (
 

 
/
 

 
; 
 
n
 
 
 

 
 142). CD8
 

 

 
/
 

 
mice were bred five generations into FVB/n before intercrossing
with HPV16 transgenic mice (N21 FVB/n), in turn producing
CD8
 

 
-deficient (
 

 
/
 

 
; 
 
n
 
 
 

 
 119) and CD8
 

 
-proficient (
 

 
/
 

 
;
 
n
 
 
 

 
 39) HPV16 mice. To minimize potential effects of genetic
drift, the crosses to maintain the HPV16 line, and the CD8
 

 
/
 

 
,
and CD4
 

 
/
 

 
 backcrosses to FVB/n were all performed at the
same time using a common FVB/n stock obtained from the The
Jackson Laboratory.
 
Tissue Preparation and Histology.
 
For paraffin sections, tissue
pieces from transgenic animals were immersion-fixed in 3.75%
paraformaldehyde and PBS or 10% zinc-buffered formalin fol-
lowed by dehydration through graded alcohols and xylene, and
embedded in paraffin. 5-
 

 
m thick paraffin sections were cut us-
ing a Leica 2135 microtome. Sections were deparaffinized and re-
hydrated through an alcohol series then subjected to histochemi-
cal or immunohistochemical staining as described previously (2).
5-
 

 
M sections were stained with hematoxylin and eosin (H&E)
for histological analysis. For frozen sections, tissue was embedded
without fixation in OCT (Tissue-Tek) and frozen on dry ice. 10-
 

 
m thick frozen sections were cut using a Leica CM1900 cry-
ostat. Sections were air-dried, fixed in acetone, and subjected to
immunohistochemical or immunofluorescence staining.
 
Immunohistochemistry and Immunofluorescence Microscopy.
 
Paraf-
fin sections were used for MMP-9, PCNA, keratin 14, keratin
10, keratin 8, pan-keratin, and vimentin substrate immunohis-
tochemistry. Dilution used for rabbit anti-MMP-9 (a gift of Dr.
Zena Werb; reference 16) was 1:1,000, 1:100 for mouse anti-
PCNA (19A2, BioGenex), 1:2,500 for rabbit anti-keratin 14
(MK14, BabCo), 1:2,500 for rabbit anti-keratin 10 (MK10,
BabCo), 1:50 for rat anti-K8 (TROMA 1, a gift of Dr. Rolf
Kemler, Max-Planck Institute for Immunobiology, Freiburg,
Germany), 1:200 for rabbit anti-pan-keratin (Biogenex), and
1:50 rabbit anti-vimentin (Vim3B4; DakoCytomation) in block-
ing solution containing PBS pH 7.4, 2.5% goat serum, and 1%
BSA. Frozen sections were used for CD4 and CD8
 

 
 immuno-
histochemistry. Dilution used for rat anti–mouse CD8
 

 
 (53–6.7;
BD Biosciences) and rat anti–mouse CD4 (H129.19; BD Bio-
sciences) was 1:200 in a blocking solution containing PBS pH
7.4 and 0.25% blocking reagent (NEN Life Science Products).
Incubation with primary antibody was overnight at 4
 

 
C. After
incubation with a biotinylated secondary antibody (goat anti–
rabbit IgG, goat anti–rat IgG, or goat anti–mouse IgM, 1:200;
Pierce Chemical Co.) for 30 min at ambient temperature, anti-
gens were revealed with 3,3
 

 
-diaminobenzidine (DAB; Sigma-
Aldrich) according to the manufacturer’s instructions. Sections
were counterstained in 1% methyl green, dehydrated in iso-
butanol and xylene, mounted in Cytoseal 60 (Stephens Scien-
tific), and visualized with Nomarski optics. All immunolocaliza-
tion experiments were repeated three times on multiple tissue
sections and included negative controls for determination of
background staining, which was negligible. All images were dig-
itally captured on a Nikon Microphot-FX microscope equipped
with a DC-330 CCD color camera (DAGE-MTI) and imaged
using Improvision OpenLab software. Frozen sections were used
for immunofluorescence staining. Dilution used for rabbit anti-
MMP-9 was 1:1,000, 1:200 for rat anti–mouse Mac-1 FITC
(CD11b, M1/70; BD Biosciences), and 1:100 for rat anti–mouse
CD4 (H129.19; BD Biosciences) in blocking solution contain-
ing PBS and 0.25% blocking reagent (NEN Life Science Prod-
ucts). Incubation with primary antibodies was 1 h at ambient
temperature followed by incubation with a Cy3 conjugated don-
key anti–rabbit IgG (Jackson Immunochemicals) secondary anti-
body at 1:200 and Cy2 conjugated donkey anti–rat IgG (Jackson
Immunochemicals) for 1 h at ambient temperature. Sections
were mounted in VectaShield containing DAPI (Vector Labora-
tories) and images were digitally captured on a Carl Zeiss Mi-
croimaging, Inc. Axioskop 2 plus equipped with a Hamamatsu-
Orca digital camera and imaged using Improvision OpenLab
software.
 
Flow Cytometry and Cell Sorting.
 
To assess total cell number
and the activation status of lymph node T cells, brachial lymph
nodes were removed and transferred to PBS. Single-cell suspen-
sions were generated using a glass homogenizer and filtered
through a 70-
 

 
m nylon filter (Falcon). Total cell counts were
performed using a Coulter Counter. Lymph node cells were
stained with either rat anti–mouse CD4 FITC (H129.19; BD
Biosciences) or CD8
 

 
 FITC (53–6.7; BD Biosciences) at a dilu-
tion of 1:20 and rat anti–mouse CD69 PE (H1.2F3; Caltag Lab-
oratories) at a dilution of 1:10 in PBS and 1% BSA (Intergen)
(PBS/BSA). Cells were incubated for 20 min at 4
 

 
C and washed
twice with PBS/BSA. A total of 20,000 gated events were col-
lected per sample on a Becton Dickinson FACSCaliber™. All
samples were stained with rat IgG Fitc and rat IgG PE controls
to determine background staining for setting gates. Values repre-
sent the mean 
 
	 
 
SE of the percentage of CD4
 

 
 or CD8
 

 
 T cells
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expressing CD69 (four or more mice per group). To quantify
and sort infiltrating cells from skin or tumors, tissue pieces were
manually minced using a scalpel, followed by a 13 min enzy-
matic digestion with 2.5 mg/ml Collagenase Type II (GIBCO
BRL), 2.5 mg/ml Collagenase Type IV (GIBCO BRL), and 0.5
mg/ml DNase (Sigma-Aldrich) in PBS/BSA at 37
 

 
C. The digest
was quenched by adding of DMEM (GIBCO BRL) containing
10% of FBS (heat inactivated; GIBCO BRL) and was filtered
through a 70-
 

 
m nylon filter (Falcon). After one wash in PBS/
BSA, the cells were incubated for 10 min in rat anti–mouse
CD16/CD32 monoclonal antibody (BD Biosciences) at a 1:10
dilution in PBS/BSA. For analysis, rat anti–mouse CD4 FITC
(1:20), rat anti–mouse CD8
 

 
 FITC (1:20), rat anti–mouse Mac-1
FITC (1:40), or rat anti–mouse Gr-1 FITC (1:60) were diluted
in PBS/BSA, incubated for 20 min at 4
 

 
C, and washed twice in
PBS/BSA. A total of 50,000 gated events were collected per
sample on Becton Dickinson FACSCalibur™. Values represent
the mean 
 
	 
 
SE of the percentage of total cells in the tissue prep-
aration (three or more mice per group). For cell sorting, 7-AAD
(BD Biosciences), a viability marker, was added at a dilution of
1:10 to the cells to ensure that only live cells were collected. The
CD4
 

 
 T cell, Mac-1
 

 
/Gr-1
 

 
 and “other” cell populations were
sorted and collected under RNase free conditions, using a high-
speed fluorescently activated cell sorter (FACSVantage™; Bec-
ton Dickinson).
 
Antigens.
 
A lysate of 
 
Staphylococcus aureus
 
 (SANSORBIN
Cells; Calbiochem) was prepared by sonication of cells in 50 mM
Tris-HCl (pH 7.4) and 150 mM NaCl. The 
 
S. aureus
 
 lysate was
passed through a sterile 0.22-
 

 
m filter and protein concentration
determined by Bradford assay (Bio-Rad Laboratories) using a
BSA standard. Endotoxin levels were measured by Limulus
ameobocyte lysate assay (BioWhittaker) and 
 
Staphylococcus aureus
 
lysates contained 38.4 endotoxin units (EU)/ml. NH
 
2
 
-terminal
histidine-tagged HPV16-E7 protein was cloned into a pET vec-
tor and expressed in 
 
E. coli
 
 strain BL21(DE3) (Novagen; bacterial
stocks a generous gift from Dr. Roland Tisch, University of
North Carolina at Chapel Hill, Chapel Hill, NC). Bacteria were
solubilized in 6 M Guanidine-HCl and purified over a Ni-NTA
Superflow column (QIAGEN). The column was washed with
1% Triton X-100/6 M Guanidine-HCl to remove endotoxin.
HPV16-E7 was eluted from the column with 6 M Guanidine-
HCl, 50 mM imidazole (pH 4.2) and dialyzed into PBS/20%
glycerol. HPV16-E7 preparations contained 
 


 
0.1 endotoxin
units (EU)/ml. Ovalbumin (Sigma-Aldrich) was used as a control
for HPV16-E7. Concanavalin A (Sigma-Aldrich) was used as a
positive control.
 
Cytokine Assays.
 
Cervical lymph nodes were removed under
sterile conditions, disrupted using glass homogenizers, washed
with PBS, and quantified by hemocytometer. Lymph node cells
were cultured in 96-well half-well flat-bottom microculture
plates (Falcon) with 1.0 
 

 
 10
 
6
 
 cells/well in 0.2 ml HL-1 serum
free media (BioWhittaker) and the indicated antigen. Class II
MHC blocking antibody (M5/114) (American Type Culture
Collection) and isotype control (BD Biosciences) were used at 50
mg/ml in the indicated cultures. Cultures were set up with repli-
cates in triplicate and incubated at 37
 

 
C in 5% CO
 
2
 
/95% air (5%
CO
 
2
 
) for 48 h. The supernatants were analyzed for IFN-
 

 
, IL-4,
and IL-3 by ELISA. Capture antibodies, cytokine standards, bio-
tinylated detecting antibodies, and streptavidin-alkaline phos-
phatase were obtained from BD Biosciences. IFN-
 

 
 capture mAb
(R46-A2) was coated at 2 
 

 
g/ml. Biotinylated IFN-
 

 
 detecting
mAb (XMG1.2) was used at 0.5 
 

 
g/ml. IL-4 capture mAb
(BVD4–1D11) was coated at 0.5 
 

 
g/ml. Biotinylated IL-4 de-
tecting mAb (BVD6–24G2) was used at 0.5 
 

 
g/ml. IL-3 capture
mAb (MP2–8F8) was coated at 2 
 

 
g/ml. Biotinylated IL-3 de-
tecting mAb (MP2–43D11) was used at 0.25 
 

 
g/ml. Strep-
tavidin-alkaline phosphatase was used at a 1:2,000 dilution.
Reference curves were generated for each assay using recombi-
nant IFN-
 

 
, IL-4, and IL-3 as standards. Optical density of
 

 
nitrophenyl phosphate (Sigma-Aldrich) substrate was deter-
mined at 405 nm on a Thermomax microplate reader (Molecular
Devices). Values represent the mean 
 
	 
 
SD of triplicates.
 
Substrate Zymography.
 
Tissue samples representing distinct
ages and SCCs from HPV16 and HPV16/CD4
 

 
/
 

 
 mice were
weighed and then homogenized (1:4 weight to volume) in lysis
buffer containing 50 mM Tris-HCl (pH 8.0), 150 mM NaCl,
0.1% NP-40, 0.5% deoxycholate, 0.1% SDS. Soluble and insolu-
ble extracts were separated by centrifugation and subsequently
stored at –80
 

 
C. Equivalent amounts of soluble extract were ana-
lyzed by gelatin zymography (17) on 10% SDS-polyacrylamide
gels copolymerized with substrate (1 mg/ml of gelatin) in sample
buffer (10% SDS, 0.25 M Tris-HCl, 0.1% Bromophenol Blue,
pH 6.8). After electrophoresis, gels were washed three times for
30 min in 2.5% Triton X-100, three times for 15 min in ddH
 
2
 
O,
incubated overnight at 37
 

 
C in 50 mM Tris-HCl, 10 mM CaCl
 
2
 
(pH 7.6), and then stained in 0.5% Coomassie Blue and
destained in 20% methanol/10% acetic acid. Negative staining
indicates the location of active protease bands. Exposure of
proenzymes within tissue extracts to SDS during gel separation
procedure leads to activation without proteolytic cleavage (18).
Zymography was done on tissue samples from mice of each ge-
notype taken from 1 mo (
 
n
 
 
 

 
 5), 3 mo (
 
n
 
 
 

 
 5), and 6 mo (
 
n
 
 
 

 
10) of age and SCCs (
 
n
 
 
 

 
 10). Data shown in Fig. 6 C are repre-
sentative of results obtained from 6-mo-old mice (
 
n
 
 
 

 
 10) and
SCC-bearing animals (
 
n
 
 
 

 
 10).
RT-PCR. Total RNA was made from CD4 and Mac-1/Gr-1
sorted cells and unsorted cells using an RNeasy kit (QIAGEN).
Total RNA was reverse transcribed by using random hexamers
(GIBCO BRL) and M-MLV reverse transcriptase (GIBCO
BRL). Specific primers were used to amplify cDNAs: MMP-9
sense, 5-CCCTGGAACTCACACGACATC-3; MMP-9 anti-
sense, 5-TCACACGCCAGAAGAATTTGC-3; CD4 sense,
5-GAGGTTCGCCTTCGCAGTTTGAT-3; CD4 antisense,
5-GGTGCAGTTCCAGAAGTCGCT-3. Primers for the ri-
bosomal protein L19 (L19 sense, 5-CTGAAGGTCAAAGG-
GAATGTG-3; L19 antisense, 5-GGACAGAGTCTTGAT-
GATCTC-3) were included in each experiment as an internal
control. 35 cycles (MMP-9 and CD4) and 31 cycles (L19) were
performed with a PTC-200 thermocycler (MJ Research) as fol-
lows: 30 s at 95, 30 s at 55, 30 s at 72. PCR products were run
on 1.5% agarose gels. Gels were photographed using an IS-1000
Digital Imaging System (Alpha Innotech Corp.).
Statistical Analysis. Flow cytometric data, immunohistochem-
istry data, and cytokine assays were analyzed using an unpaired t
test (InStat v1.12; GraphPad Software). Pre-malignant pathology
was analyzed using a chi-squared test for trend (InStat v3.0;
GraphPad Software). Tumor-free survival was analyzed using a
log-rank test (Prizm 3.0A; GraphPad Software).
Results
T Cells Infiltrate Dysplasias and Squamous Carcinomas.
To determine if T lymphocytes were associated with the
distinctive stages of epidermal carcinogenesis, we analyzed
dysplastic (premalignant) epidermis and tumors (invasive
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squamous cell carcinomas, SCCs) from K14-HPV16 mice
for the presence of T cells by immunohistochemistry. Us-
ing a monoclonal antibody specific to CD4, we observed
CD4 T cell infiltration in dysplastic skin (Fig. 1 A) and tu-
mors (Fig. 1 B). However, little to no T cell infiltration was
detected in more benign hyperplastic lesions (data not de-
picted) or in control skin from nontransgenic mice (Fig. 1
C). Immunohistochemistry to detect CD8 T cells did not
reveal an appreciable infiltration of hyperplastic and dys-
plastic lesions, whereas a low level infiltrate was detected in
SCCs (unpublished data).
To provide a quantitative measure of the degree of infil-
tration, we analyzed nontransgenic skin, dysplastic skin,
and tumors by flow cytometry. Single cell suspensions were
generated by subjecting tissue to mechanical disruption fol-
lowed by enzymatic digestion of the extracellular matrix.
As expected from immunohistochemical analysis, we ob-
served more CD4 T cells than CD8 T cells in both dys-
plastic skin and solid tumors (Fig. 1 D)
Lymph Nodes Draining Sites of Epidermal Neoplasia Contain
Activated CD4 T Cells Reactive to Bacterial Antigens. In an
effort to characterize the T cell responses observed in pre-
malignant dermis, we analyzed T cells from the draining
lymph nodes. The brachial lymph nodes that were draining
premalignant lesions of the epidermis showed a significant
increase in total cellularity (nontransgenic 4.1  106 cells
vs. HPV16 40.8  106 cells; P  0.0079, unpaired t test).
Furthermore, we analyzed brachial lymph node cells for
evidence of T cell activation by determining the fraction of
cells expressing the early activation marker CD69. In
HPV16 mice with tumors, 24% of the CD4 T cells in
the draining lymph nodes were expressing CD69, in con-
trast to 7% CD69CD4 T cells in control nontrans-
genic mice (P 
 0.0001, unpaired T test; Fig. 2 A). We
observed a minimal increase in activated CD8 T cells,
from 5% CD69CD8 cells in nontransgenic control
skin to 9% in tumor-bearing HPV16 mice (P  0.0095,
Wilcoxon test; Fig. 2 A).
Figure 1. T cells infiltrate sites of neoplasia in HPV16 transgenic mice. (A–C) Immunolocalization of CD4 (brown staining) in skin sections counter-
stained with methyl green from HPV16 dysplastic ear skin (A), a HPV16 Grade II SCC (B), and a normal nontransgenic ear (C). The epidermal (e), der-
mal (d), malignant tumor keratinocytes (t), and tumor stroma (s) regions of the tissues are indicated. The epithelial basement membrane is marked with a
dashed line. Bar: 10 m (A, C); 30 m (B). (D) Tissue digests from normal and HPV16 transgenic skin were analyzed by flow cytometry for their CD4
or CD8 T cell content of as a percentage of total cells. Normal nontransgenic skin was obtained from 2-mo-old FVB/n mice, dysplastic skin was ob-
tained from 6–8-mo-old HPV16 mice, and tumors were obtained from 8–14-mo-old HPV16 mice. We collected 50,000 events per sample from normal
nontransgenic ear skin (blue, n  4), HPV16 dysplastic ear skin (orange, n  5), and HPV16 tumors (yellow, n  7). Results are shown as mean percent-
ages 	 standard error of the mean.
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We surmised that the activated T cells could be respond-
ing to ‘tumor antigens’ expressed in the neoplasms in par-
ticular the HPV16 oncoproteins encoded by the K14-
HPV16 transgene. Indeed, the E6 and E7 oncoproteins are
well-characterized tumor antigens in human cervical cancer
(19). However, in many cases, self-tolerance has been es-
tablished toward transgene products in mice resultant to
expression during embryogenesis, obviating immunoreac-
tivity, even in the case of tumorigenesis (20, 21). There-
fore, we first asked whether the K14-HPV16 mice were
tolerant of the E7 gene product, by immunizing nontrans-
genic and HPV16 mice with recombinant HPV16-E7 pro-
tein. Both control and HPV16 transgenic mice demon-
strated CD4 T cell reactivity, indicating the transgenic
mice were nontolerant and capable of developing an im-
mune response to E7 (unpublished data). Furthermore, the
HPV16 mice developed spontaneous autoantibodies against
E7, further supporting the lack of self-tolerance induction
toward the transgenic oncoprotein (unpublished data).
Therefore, we asked whether the reactive lymph nodes in
the HPV16 transgenic mice contained T cells specific for
E7. Lymph node cells from cervical nodes draining dysplas-
tic skin lesions were stimulated with recombinant HPV16-
E7, and supernatants analyzed for IFN- release (Fig. 2 B).
Surprisingly, the HPV16 lymph node cells did not show a
measurable response toward the HPV16-E7 protein (Fig. 2
B), indicating that their abundance was low, albeit appar-
ently sufficient to support the observed humoral response.
Because HPV-E7–responsive T cells were evidently rare
and thus could not readily explain the abundance of acti-
vated T cells in the reactive lymph nodes, we considered
other explanations. We suspected that the neoplastic, hy-
perkeratotic skin was impaired in its barrier function, and
might be allowing fortuitous bacterial infections to take
hold, evoking an immune response. Indeed, when we eval-
uated both nontransgenic normal skin and dysplastic trans-
genic skin biopsies for bacteria, rampant infection was de-
tected only in lesional skin; predominant amongst the
bacteria were gram-positive Staphylococcus aureus and Staphy-
lococcus epidermidis (Table I). Therefore, we asked whether
the reactive draining lymph nodes had developed T cell re-
sponsiveness to Staphylococcus aureus proteins, using bacterial
lysates as an antigenic source in standard T cell assays (Fig. 2
B). A proinflammatory IFN- response by lymph node T
cells was observed in response to the S. aureus lysate in
HPV16 mice, but not in naive nontransgenic mice. Fur-
thermore, this response was inhibited by including a class II
MHC (I-Aq) blocking antibody, indicating that this was a
CD4 T cell response toward a class II–restricted Staphylo-
coccal antigen. To determine the cytokine profile of the
CD4 T cell response, the supernatants were also tested for
IL-3 and IL-4 release. There was no detectable IL-3 or IL-4
production under any of the conditions tested (unpublished
data). Thus, the Staphylococcus-reactive CD4 T cells dis-
played a Th1 proinflammatory phenotype.
Genetic Deletion of CD4 T Cells Decreases the Incidence of
Carcinomas. To assess the functional significance of the
observed T cell infiltrate in premalignant lesions during
neoplastic progression, we took a genetic approach, using
mice carrying homozygous disruptions of either the CD4
or CD8 genes (14, 15). An ancillary motivation was to as-
sess the possibility that immune surveillance might underlay
the slow time to progression from angiogenic dysplasias,
and the 50% penetrance of that progression to invasive
squamous cell carcinomas. We backcrossed the CD4-null
mutation to n14 in the FVB/n mouse strain before gener-
ating HPV16/CD4/ mice (n  142), whose phenotype
was monitored over a one year time-course, revealing
significant differences. HPV16/CD4/ mice showed a
Figure 2. Activated CD4 T cells are reactive to Staphylococcus aureus.
(A) Brachial LNCs from normal nontransgenic mice (blue, n  6),
HPV16 mice with epidermal dysplasias (orange, n  4), and HPV16 mice
with tumors (yellow, n  4) were analyzed by flow cytometry for the per-
cent of gated CD4 or CD8 T cells expressing CD69. We collected
10,000 gated events per sample. Results are shown as mean percentages 	
standard error of the mean. (B) Cytokine assay of cervical LNCs from
6–8-mo-old normal nontransgenic mice (blue, n  5) or HPV16 mice
(orange, n  5) were prepared as a single cell suspension and cultured in
the presence of medium, 100 g/ml ovalbumin (2.8 M), 40 g/ml
HPV16-E7 (2.8 M), a control lysate, or 20 g/ml S. aureus lysate. To de-
termine if the response was class II restricted, cultures stimulated with the
S. aureus lysate were treated with a class II MHC blocking antibody (M5/
114; P  0.0127; unpaired t test) or isotype control (P  0.0521; unpaired
t test) and compared with S. aureus lysate stimulated cells. LNCs (1.0 
106/well) were incubated for 48 h in HL-1 medium. LNCs were stimu-
lated with 0.25 g/ml Con A as a positive control. All mice displayed sim-
ilar Con A responses (unpublished data). Supernatants were collected and
analyzed for IFN- production by ELISA. The results shown are mean 	
standard deviation of triplicate cultures from a representative experiment.
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marked delay in the kinetics of progression to squamous
carcinomas by a defined endpoint of 12 mo of age (P 
0.0107, log-rank test; Fig. 3 A). At 6 mo of age, only
53% of HPV16/CD4/ mice manifested focal dyspla-
sias, characterized by loss of terminal differentiation and in-
creased proliferation of keratinocytes; by contrast, dysplasia
is observed in 92% of control HPV16 animals (P 
0.0175, chi-squared test for trend; Fig. 3 B). Assessing an-
other parameter of neoplasia, we determined the prolifera-
tion index of premalignant lesions from HPV16/CD4/
mice by immunohistochemical analysis of tissue sections for
up-regulation of PCNA (proliferating cell nuclear antigen).
We also observed a modest decrease in proliferation index
in HPV16/CD4/ mice (38.4 	 1.8%) as compared with
HPV16/CD4/ control mice (42.8 	 2.4%; P  0.1339;
unpaired t test). The HPV16/CD4/ mice also exhibited
a reduced incidence of squamous carcinomas by the 12-mo
endpoint. Only 41% of HPV16/CD4/ mice developed
tumors, in contrast to the 52% incidence in CD4-compe-
tent HPV16 mice.
Tumors arising in immune competent HPV16 mice dis-
play a spectrum of carcinoma grades, based on characteristic
epithelial differentiation markers (5). The anatomical distri-
bution and average number per mouse (1.3) of tumors in
HPV16/CD4/ mice was comparable to the immune
competent HPV16 mice (unpublished data).
In a comparable analysis, CD8/ mice were back-
crossed five generations into FVB/n and then intercrossed
with HPV16 mice to produce HPV16 mice that lacked
CD8 T cells. We aged a cohort of CD8/ HPV mice for
1 yr, comparing their neoplastic phenotype to CD8/
HPV littermates. The absence of CD8 T cells slightly de-
layed the temporal appearance of invasive cancers (n 
119; P  0.0011, log rank test; unpublished data); how-
ever, in contradistinction to the situation when the CD4
T cells were missing, the absence of CD8 T cells did not
alter the overall incidence of invasive cancers arising by
the defined endpoint of 12 mo, either in comparison to
CD8/ littermates or historical control CD8/ HPV mice.
Thus, there was no evidence for CD8 T cell mediated im-
mune surveillance in the form of an more aggressive tumor
phenotype in their absence, but rather a suggestion of weak
immune enhancement of tumor progression mediated by
CD8 T cells.
Infiltration of Dysplasias by Innate Immune Cells Is Decreased
in HPV16/CD4/ Mice. Previous studies in this model
revealed an important role for bone marrow–derived in-
flammatory cells (mast cells, macrophages, and neutrophils)
in supplying MMP-9, itself a demonstrably important func-
Table I. Microbial Analysis of Skin from HPV16 Mice
Genotype
Staphylococcus
aureus
Staphylococcus
epidermidis
HPV16  
HPV16  
HPV16  
HPV16/CD4/  
HPV16/CD4/  
HPV16/CD4/  
NTg  
NTg  
NTg  
Ear and chest skin from normal non-transgenic FVB/n (NTg) and
HPV16 mice between 8 and 12 mo of age was removed under sterile
conditions and submitted to IDEXX Veterinary Services (Sacramento,
CA) for identification and quantification of aerobic bacteria present
within the tissue by semiquantitative limiting dilution analysis. Results
shown are from ear skin in which both Staphylococcus aureus and
Staphylococcus epidermidis were detected. The data shown is on a scale of
one to four (). All other aerobic microbial species were one () or
lower. Equivalent infection was observed in chest skin.
Figure 3. HPV16/CD4/ mice show delayed tumorigenesis. (A) Per-
centage of SCC-free transgenic mice in two cohorts: HPV16/CD4/,
n  142 (FVB/n N14-N20; blue triangles) and HPV16/CD4/, n  142
(FVB/n N14; orange diamonds). HPV16/CD4/ mice exhibit an overall
tumor incidence of 52%. In contrast, the incidence of tumors in HPV16/
CD4/ mice was reduced to 41% (Fisher’s Exact test, P  0.0954; log-
rank test, P  0.0107). (B) A shift toward lower grade premalignant le-
sions in HPV16/CD4/ mice. 6-mo-old ear skin from HPV16/CD4/
mice (blue, n  12) and HPV16/CD4/ (orange, n  19) was collected
and graded based on criteria previously described (reference 2) and sum-
marized in Materials and Methods. HPV16/CD4-deficient mice exhibited
an altered spectrum of premalignant skin lesions biased toward less malig-
nant lesions (P  0.0175, chi-squared test for trend).
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tional contributor to squamous carcinogenesis in HPV16
mice (4, 5). Recognizing that CD4 T cells can recruit
both macrophages and neutrophils into tissue sites and acti-
vate them therein, we analyzed HPV16/CD4/ mice for
evidence of changes in the inflammatory infiltrate. A signif-
icant inflammatory infiltrate is characteristic both in neo-
plastic skin of 6-mo-old immune competent HPV16 mice
as well as in invasive tumors. Therefore, we compared dys-
plastic skin lesions from age matched 6-mo-old mice and
tumors from HPV16/CD4/ and HPV16/CD4/ mice
for differences in inflammatory cell populations. Single cell
suspensions were generated by subjecting tissue to mechan-
ical disruption followed by enzymatic digestion of the ex-
tracellular matrix (ECM). To quantify the inflammatory in-
filtrate, we used flow cytometry to assess the infiltration of
cells expressing the cell surface molecules Gr-1 (Ly-6G)
and Mac-1 (CD11b). Gr-1 is expressed on neutrophils and
Mac-1 (CD11b) is expressed on granulocytes, macro-
phages, dendritic cells, and natural killer cells.
There was a significant decrease in the number of inflam-
matory cells expressing Mac-1 In lesional skin from 6-mo-
old HPV16/CD4/ mice compared with their CD4 profi-
cient counterparts (P  0.0136, unpaired t test; Fig. 4).
HPV16/CD4/ mice had a Mac-1 cell infiltrate repre-
senting 30% of the total cells within the skin, whereas
HPV16/CD4/ mice showed a 15% Mac-1 infiltrate.
We observed a similar decrease in Gr-1 cell infiltrates in
CD4-null dysplasias (P  0.0425, unpaired t test; Fig. 4). In
contrast, when solid tumors from HPV16/CD4/ mice
were analyzed for either Mac-1 or Gr-1 cell infiltration,
no significant difference was observed in comparison to im-
mune competent HPV16/CD4/ mice (P  0.6047 for
Mac-1, P  0.7520 for Gr-1, unpaired t test; Fig. 4). Tu-
mors from both HPV16/CD4/ and HPV16/CD4/
mice contained 20% infiltration by Mac and Gr-1 cells.
Fewer MMP-9–expressing Cells and Decreased MMP-9 Ac-
tivity in HPV16/CD4/ Mice. Previous studies have
shown that activity of the matrix metalloproteinase MMP-9
is induced during neoplastic progression in HPV16 mice
(5). Furthermore, functional assessment of MMP-9 in
HPV16/MMP-9/ mice revealed its activity to be impor-
tant, in that absence of MMP-9 resulted in delayed neo-
plastic progression and a lower incidence of squamous car-
cinomas. Since we observed a decrease in the inflammatory
infiltrate in HPV16/CD4/ mice, biopsies of premalig-
nant 6-mo-old skin and tumors from HPV16/CD4/
mice were analyzed for MMP-9 expression by immunohis-
tochemistry. In lesional skin of HPV16/CD4/ mice, we
observed a 60% decrease in the number of cells express-
ing MMP-9 as compared with HPV16/CD4/ mice (P 
0.0087, unpaired t test; Fig. 5 A). HPV16/CD4/ mice
had 1,200 MMP-9 cells per mm2; whereas HPV16/
CD4/ mice had 500 MMP-9 cells per mm2. This dif-
ference is consistent with the 50% decrease in the inflam-
matory infiltrate detected by flow cytometry. In contrast,
tumors from HPV16/CD4/ mice showed no decrease in
number of MMP-9 cells compared with control HPV16
mice (Fig. 5 B), much as they showed no difference in the
overall abundance of infiltrating immune cells (Fig. 4). Tu-
mors from both genotypes showed 1,800 MMP-9 cells/
mm2. Thus, the immunohistochemical analysis indicated a
selective decrease in the abundance of MMP-9 cells in
premalignant dysplastic skin lesions but not squamous car-
cinomas of CD4-null HPV mice.
To determine if the decrease in MMP-9 cell infiltrate
in premalignant HPV16/CD4/ skin affected tissue
MMP-9 enzyme activity, we analyzed lysates from neoplas-
tic skin obtained from HPV16/CD4/ mice of varying
ages (and stages of disease progression) for proteolytic activ-
ity using gelatin substrate zymography. As previously re-
ported (5), the pro-enzyme and active forms of MMP-9 are
not found in normal FVB/n skin (unpublished data). Both
the pro-enzyme and active forms of MMP-9 were detected
at similarly low levels in skin lysates from 1- and 3-mo-old
HPV16/CD4/ and control HPV16 mice (unpublished
data). As expected, both forms of MMP-9 were found at
markedly higher levels in 82% of 4–6-mo-old HPV16 skin
lysates containing angiogenic dysplasias (n  66) and in
95% of solid tumors (n  26; Fig. 5 C). In contrast, only
30% of HPV16/CD4/ mice showed similarly high
levels of active MMP-9 in neoplastic lesions from age-
matched 4–6-mo-old mice (Fig. 5 C), and only 20% of
squamous carcinomas displayed abundant levels of active
MMP-9 (Fig. 5 C).
MMP-9 Is Not Expressed by Infiltrating CD4 T Cells.
MMP-9 has previously been detected by immunostaining in
granulocytes, macrophages, and mast cells found in associa-
tion with neoplastic lesions in HPV16 mice, using morpho-
logical criteria to identify the immune cell types. This pat-
tern was consistent with the finding that bone marrow from
wild-type MMP-9/ mice restored the characteristic
HPV16 phenotype when transferred to HPV16/MMP-9/
mice (5). To determine if CD4 T cells infiltrating tumors
Figure 4. Reduced inflammatory infiltrate in HPV16/CD4/ skin.
Tissue digests from HPV16/CD4/ (blue) and HPV16/CD4/ (or-
ange) 6-mo-old skin (n  5) and SCCs (n  3) were analyzed by flow cy-
tometry for their content of Mac-1 or Gr-1 cells as a percentage of total
cells. We collected 25,000 events per sample. Results are shown as mean
percentages 	 standard error of the mean. A 50% reduction (*) in the
numbers of Mac-1 (P  0.0136; unpaired t test) and Gr-1 (p  0.0425;
unpaired t test) cells was observed in 6-mo-old ear skin from HPV16/
CD4/ mice as compared with HPV16/CD4/ mice. No reduction in
Mac-1 or Gr-1 infiltrate was observed in SCCs from HPV16/CD4/
mice (Mac-1, P  0.6047; Gr-1, P  0.7520; unpaired t test).
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were also producing MMP-9, we used fluorescence acti-
vated cell sorting to fractionate CD4 T cells and Gr-1/
Mac-1 cells from a single cell suspension prepared from tu-
mors. Total RNA was isolated from the sorted cell popula-
tions and used to prepare cDNA for PCR analysis using oli-
gonucleotide primers specific to MMP-9, CD4, and L19 (a
housekeeping gene). MMP-9 mRNA was only detected in
the Gr-1/Mac-1 and unlabelled (OC) populations (Fig. 6
A). After 35 cycles of PCR, no MMP-9 product was de-
tected in the CD4 T cell population. In contrast, a promi-
nent PCR product was detected in the Gr-1/Mac-1 cell-
derived cDNA. As a positive control for the fractionation
method, the CD4 T cell population was tested for the ex-
pression of CD4 mRNA and found to be positive.
The results of the RT-PCR analysis indicated that
MMP-9 mRNA was expressed in the Gr-1/Mac-1 cells,
not CD4 T cells. We sought to confirm these results by
analyzing MMP-9 protein expression by immunostaining
of tissue sections. HPV16 tumors were assessed for MMP-9
and either Mac-1 or CD4 colocalization with specific anti-
bodies. As expected, we observed significant colocalization
of MMP-9 and Mac-1 on cells within squamous carcino-
mas (Fig. 6 B). In contrast, no colocalization of MMP-9
and CD4 were observed (Fig. 6 C). These results are con-
sistent with the finding that MMP-9 mRNA is expressed
in Mac-1/Gr-1 cells, but not CD4 T cells. From these
data, we can conclude that CD4 T cells participate in the
recruitment of MMP-9 inflammatory cells into neoplastic
lesions, but do not themselves produce the MMP-9 that
contributes to the malignant progression.
Discussion
This study has revealed an unexpected role for CD4 T
cells in the regulation of squamous carcinogenesis. Using
CD4 gene knockout mice that lack traditional helper T
Figure 5. Reduced numbers of MMP-9 cells infiltrating HPV16/
CD4/ skin. Immunolocalization and quantification of MMP-9 cells in
HPV16/CD4/ and HPV16/CD4/ 6-mo-old skin (A) and SCCs (B).
MMP-9 cells/mm2 was obtained by counting the total number of
brown cells (MMP-9) and dividing that by the total area in a field subja-
cent to the epidermis for a total of five 20 microscope fields per mouse
for five mice per group (n  5). A 60% reduction (*) in the MMP-9
cells/mm2 was observed in 6-mo-old skin from HPV16/CD4/ mice
relative to HPV16/CD4/ mice (A; P  0.0087, unpaired t test), but no
significant difference in infiltrating cells was observed in SCCs from
HPV16/CD4/ mice (B; P  0.5476, Wilcoxon test). (C) Gelatin-sub-
strate zymography of skin biopsy lysates from HPV16/CD4/ controls,
HPV16/CD4/ 4–6-mo-old ear skin (premalignant) and carcinomas.
Arrows indicate location of enzymatic activity corresponding to pro- and
active forms of MMP-9 and MMP-2.
Figure 6. MMP-9 is expressed by Mac-1 cells not CD4 T cells. (A)
RT-PCR analysis of cell populations isolated from an HPV16 tumor by
FACS®. Total RNA from CD4, Mac-1/Gr-1, and unlabelled cells
was made and reverse transcribed into cDNA. PCR for MMP-9 (35 cy-
cles), CD4 (35 cycles), and L19 (housekeeping gene; 31 cycles) was per-
formed on the cDNA from the three populations. The product was run
on a 1.5% agarose gel and the results are shown with RT and –RT dis-
played for each population of cells. (B) Immunolocalization of MMP-9
(red) and Mac-1 (green) in a tumor from an HPV16 mouse. MMP-9 and
Mac-1 are found to be colocalizing (yellow) on many cells within the tu-
mor. The inset shows a higher magnification of several cells staining for
both MMP-9 and Mac-1. Bar: 20 m; 10 m (inset). (C) Immunolocal-
ization of MMP-9 (red) and CD4 (green) in a tumor from an HPV16
mouse. No colocalization of MMP-9 and CD4 was observed. Bar: 7 m.
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cells, we found that CD4 T cells were enhancing the pro-
gression of epidermal hyperplasias to dysplasias via facilitat-
ing the recruitment of neutrophils (and potentially other
Mac-1 leukocytes). These innate immune cell types are in
turn demonstrably important for angiogenesis and neoplas-
tic cell proliferation through their provision of MMP-9.
While T cells were found inside solid tumors, their absence
did not impact tumor growth, suggesting that their ‘helper’
functions were most important for the premalignant phase
of squamous carcinogenesis. Remarkably, CD4 T cell re-
activity was predominantly directed toward antigens ex-
pressed by the Staphylococcal bacteria infecting the dys-
plastic skin lesions, suggesting that infections of neoplastic
skin evoke an inflammatory response that inadvertently en-
hances malignant progression.
A Link between Infection and Cancer. The etiologies of
several forms of human cancer are associated with infection
by parasites, viruses, or bacteria (for a review, see reference
22). In some instances, the pathogen provides oncogenes
that can directly transform the target cell, in a rather
straightforward causal relationship (23, 24). By contrast, an-
other class of pathogens does not appear to directly trans-
form the target cell, but instead, induces a state of chronic
inflammation that can ultimately lead to genetic damage in
the target tissue, resulting in transformation of the cells and
tumor development. There is evidence that the chronic
immune response to hepatitis B virus (HBV) or hepatitis C
virus (HCV) contributes to the transformation of hepato-
cytes, remodeling of the stroma, and progression to hepato-
cellular carcinoma (25). Helicobacter pylori infection of gas-
tric epithelium is associated with the development of
gastric lymphomas (maltomas) and gastric adenocarcinomas
(for a review, see reference 26). H. pylori infection of gas-
tric epithelial cells initiates a host immune response by in-
duction of IL-8 expression (27). IL-8 recruits inflammatory
cells, including proinflammatory Th1 cells and B cells (28).
A state of chronic inflammation sustained by H. pylori re-
sults in an environment enriched for DNA damaging reac-
tive oxygen and nitrogen species. This can lead to the
transformation of either the gastric epithelium or the infil-
trating B cells. Elimination of H. pylori infection using anti-
biotics can reverse the premalignant changes associated
with the inflammatory response (29).
We have documented gram-positive Staphylococcus infec-
tions of the dysplastic epidermis from HPV16 mice with a
concomitant S. aureus–reactive T cell response detectable
in the draining lymph nodes. The high proportion of acti-
vated CD4 T cells and lymphadenopathy would suggest a
state of chronic inflammation that is similar to what is ob-
served in the gastric epithelium during H. pylori infection.
Furthermore, when CD4 T cell responses were elimi-
nated in HPV16/CD4/ mice, a delay to malignant pro-
gression and decrease in the incidence of SCCs was ob-
served. While no link has been observed between
Staphylococcus infection and squamous cancer in humans,
the observation has relevance and implications for model-
ing human cancers associated with a chronic immune re-
sponse to a pathogen. In two different mouse models of co-
lon cancer, spontaneous adenocarcinomas were prevented
when the mice were housed under germ-free conditions
(30, 31); in the later example, when Helicobacter hepaticus
bacteria was reintroduced into the mice, tumors again de-
veloped (31). Similarly, we are in the process of transferring
HPV16 mice into a germ-free notobiotic environment to
clarify the functional importance of bacterial infection for
squamous carcinogenesis of the skin.
Absence of Immune Surveillance. The HPV16 mice de-
velop multifocal angiogenic dysplasia by 6 mo with 100%
penetrance, and yet only one invasive carcinoma emerges
on average in 50% of the mice by a defined endpoint of 1
yr of age. We hypothesized that immune surveillance could
be restricting the appearance of invasive carcinomas (32),
particularly when we detected spontaneous anti-E7 au-
toantibodies indicative of an anti-HPV immune response.
Several epidemiological studies have demonstrated that the
incidence and severity of HPV-associated cervical or ano-
genital neoplasias are higher in HIV-positive immunocom-
promised humans (33, 34). Furthermore, a similar increase
in nonmelanoma skin cancer is observed in transplant pa-
tients receiving pharmacological immunosuppression (35).
Thus, when we crossed in the CD4 and CD8 gene knock-
outs, we expected earlier appearance of tumors, increased
numbers of tumors per animal, and a higher incidence of
tumors in the population (above the 50% seen in wild-type
HPV mice). Instead, absence of CD8 T cells caused a
slight delay in the appearance of tumors, whereas absence
of CD4 T cells both delayed the temporal appearance and
reduced the incidence of tumors.
The HPV mice have an unusual form of ‘split tolerance’
toward HPV E7 (and E6) oncoproteins. We have demon-
strated humoral nontolerance and autoreactivity in the
form of spontaneous and inducible antibody responses to-
ward E7, in data to be presented elsewhere. As for the cy-
totoxic T cell compartment, the H-2q class I MHC alleles
present in the FVB/n strain are incapable of presenting E7
or E6 epitopes (36), and thus CD8 T cells are immunolog-
ically ignorant of these oncoproteins. There is no informa-
tion available regarding antigenicity of the E1 – E5 pro-
teins that are presumably also expressed in addition to E6
and E7 in the K14-HPV16 mice, which carry the entire
HPV16 early region. In any event, there is no evidence
that immune surveillance underlies the long latency and
incomplete penetrance of cancer observed in the HPV16
model; however, we leave open the possibility that im-
mune surveillance could become a factor if full immune
recognition in the CD8 compartment was achieved. To
that end, we have begun the process of rendering the
HPV16 mice congenic for the H-2b MHC but otherwise
inbred into the FVB/n background that conveys suscepti-
bility for the invasive phenotype, such that we can further
probe the potential of immune surveillance as a biological
mechanism. Moreover, the clue that CD8 T cells might
have weak tumor-enhancing activity is complicated by the
incomplete backcrossing into FVB/n of the CD8 knock-
out locus, which in principle could be cosegregating a
closely linked modifier locus; thus definitive analysis of the
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roles, if any, of CD8 T cells awaits more complete in-
breeding of the CD8 locus, and its combination with the
H-2b MHC in the context of the FVB/n background in
HPV transgenic mice.
One might similarly attribute the absence of immune
surveillance seen when comparing CD4/ and CD4/
animals trivially to the genetic ignorance of cytotoxic T
cells toward E6/7 peptides or to polymorphic modifier
genes cosegregating with the CD4-ko gene. Other data,
however, suggest that neoplastic enhancement and lack of
effective surveillance by CD4 T cells is a genuine attribute
of this immune cell type in this particular organ, the skin.
When K14-HPV16 mice are treated with sustained low
dose estrogen, cervical carcinogenesis ensues (37, 38). If
HPV16 females are rendered CD4 deficient via the same
crosses (and backcross generations) as studied in this report,
a much different tumor phenotype is seen: cervical carcino-
mas develop in greater number and are larger in the
HPV16 mice that lack CD4 T cells, indicating that in the
cervix, CD4 T cells antagonize rather than enhance car-
cinogenesis, consistent with an immune surveillance role
(unpublished data). Thus we conclude that CD4 T cells
can have both the predicted ability to interfere with tumor
progression as well as the unexpected ability to functionally
enhance carcinogenesis via helping innate immune cell
type supply pro-angiogenic MMP-9; these distinct roles
can be seen in different organs of otherwise genetically
identical mice.
T Cells, Innate Immunity, and Cancer. An emerging
view of cancer is that tumors are manifestations of a com-
plex multicellular disease, involving genetic mutations in
neoplastic cells in concert with the recruitment of support-
ing cells, including fibroblasts, endothelial cells, and in-
flammatory cells, that functionally contribute to the tu-
mor’s capabilities (39). In this report, we document the
development of a significant inflammatory infiltrate during
neoplastic progression in HPV16 mice. We detect both
CD4 T lymphocytes (1–5%) and Mac-1/Gr-1 cells
(20–30%) within premalignant lesions and cancers. Both
macrophages and neutrophils of the innate immune system
are represented in the Mac-1/Gr-1 infiltrate. Mast cell
infiltration of premalignant dermis underlying dysplastic
epidermis and the contribution of mast cells to malignant
progression has been previously documented (4). Several
types of cancer are associated with chronic inflammation of
both infectious and noninfectious origin (for a review, see
reference 40). Esophageal carcinoma is associated with
chronic inflammation of the lower esophagus caused by
stomach acid reflux (41). Mesothelioma is associated with a
chronic inflammatory response to inhaled asbestos fibers
(42). Thus, whether induced by an infectious agent, as with
H. pylori infection, or other tissue injury, the feature com-
mon to these forms of malignancy is a state of chronic in-
flammation associated with immune cell infiltration.
Recent work in a transgenic mouse model of mammary
cancer (PyMT mice) established an important role for mac-
rophages in the development of invasive carcinomas and
pulmonary metastasis (12). In PyMT mice rendered defi-
cient in macrophage colony stimulating factor–1 (CSF-1),
the neoplastic epithelial cells failed to recruit mature mac-
rophages into the neoplastic tissue, resulting in decreased
malignancy. We observe a similar effect in HPV16/CD4/
mice, in that premalignant lesions displayed a significant
decrease in the leukocyte infiltrate associated with delayed
progression, and a decreased incidence of carcinomas. Infil-
trating leukocytes are known to express and release an array
of cytokines, chemokines, growth factors, free radicals, and
proteases. Among these, MMP-9 expressed by bone mar-
row–derived cells has been previously shown to contribute
to malignant progression in the skin of HPV16 mice (5).
Now we report that, MMP-9 activity is significantly lower
in the neoplastic lesions of HPV16/CD4/ mice. Thus,
elimination of CD4 T cells reduced infiltration by macro-
phages and neutrophils, resulting in a decrease in MMP-9
within the premalignant lesions. CD4 T cells have previ-
ously been documented to produce MMP-9 when stimu-
lated by a phorbol ester (43); in contradistinction, we
found no evidence of MMP-9 mRNA in CD4 T cells
fractionated from tumors by flow cytometry. Rather,
MMP-9 mRNA and protein were detectable in similarly
fractionated cells of the Mac-1 lineage.
Perspective on Tumor Immunity versus Immune Enhance-
ment. The realization that CD4 T cells can enhance (as
opposed to antagonize) tumor progression raises an impor-
tant question for experimental strategies aimed at inducing
antigen-specific tumor immunity: do all antitumor immune
responses include both destructive and enhancing function-
alities, balanced to varying degrees? In one recent study
aimed to induced tumor immunity, the opposite resulted:
T cell–mediated enhancement of benign papilloma devel-
opment was observed in two-step skin tumor model in-
volving Harvey ras transgenic mice treated with PMA, in
that preimmunization to elicit an anti-ras immune response
enhanced (rather than protected against) papilloma forma-
tion (10). On the other hand, immunization of transgenic
mice developing prostate cancer with an irradiated tumor
cell vaccine significantly reduced the incidence of prostate
tumors (44). Furthermore, we have immunized K14-
HPV16 female transgenic mice developing cervical cancer
(37) with an HPV16-E7 vaccine, and reduced the inci-
dence of cervical cancer (unpublished data). These latter
examples argue that efficacious tumor antigen-specific
immunity can be induced; one wonders, nevertheless,
whether the efficacy observed in each of these cases might
have been attenuated by concurrent immune enhance-
ment? Our perspective is that successful immunotherapies
in the future may well combine tumor antigen-specific im-
mune activators with selective inhibitors of the tumor-
enhancing effects of inflammation, biasing the immune re-
sponse solely for destruction of cancerous lesions.
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